APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncolytic Virus

An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumor. Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumor. Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Selected research

Market Outlook & Growth Opportunities

Global Oncolytic Virus Market Outlook and Growth Opportunities 2026

30 December 2025194 pages

Choose your research edition.

Industry ResearchOncolytic Virus Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncolytic Virus Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Oncolytic Virus Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncolytic Virus Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncolytic Virus Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumor. Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

To date, two genetically engineered oncolytic viruses have been approved for marketing as drugs. One is Oncorine (H101, the same construct as ONYX‐015),9 an E1B‐deleted adenovirus, which was approved in China for head and neck cancer and esophagus cancer in 2005. The use and clinical data of Oncorine is so far limited to China. The other is T‐Vec (talimogene laherparepvec, IMLYGIC, formerly OncoVEXGM‐CSF), which was approved for melanoma by the FDA in the USA in October 2015 and was subsequently approved in Europe in January 2016 and in Australia in May 2016. For developing product, there are 3 products in Phase 3, 8 products in Phase 2, 7 products in Phase 1 and 3 products in Preclinical. Market competition is intense. Amgen, Shanghai Sunway Biotech, Oncolytics Biotech, Viralytics, Transgene SA are the leading developers in the industry; with high investment in research marketing and they will monopoly position in the industry. Other players include Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics, Sorrento Therapeutics, Lokon Pharma, Genelux Corporation, Vyriad, TILT Biotherapeutics and Cold Genesys, etc.

This report provides an overview of the global Oncolytic Virus market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Oncolytic Virus and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncolytic Virus sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oncolytic Virus market size, projected growth trends, production technologies, key applications, and end-use industries.

Oncolytic Virus Segment by Company

Amgen

Shanghai Sunway Biotech

Oncolytic Virus Segment by Type

Imlygic

Oncorine

Others

Oncolytic Virus Segment by Application

Melanoma

Other Cancers

Oncolytic Virus Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oncolytic Virus status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oncolytic Virus market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncolytic Virus significant trends, drivers, influence factors in global and regions.

6. To analyze Oncolytic Virus competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oncolytic Virus market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncolytic Virus industry.

Chapter 3: Detailed analysis of Oncolytic Virus manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oncolytic Virus in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oncolytic Virus in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncolytic Virus Industry Trends Table 2. Oncolytic Virus Industry Drivers Table 3. Oncolytic Virus Industry Opportunities and Challenges Table 4. Oncolytic Virus Industry Restraints Table 5. Global Oncolytic Virus Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncolytic Virus Revenue Share by Company (2021-2026) Table 7. Global Oncolytic Virus Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Oncolytic Virus Sales Volume Share by Company (2021-2026) Table 9. Global Oncolytic Virus Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Oncolytic Virus Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oncolytic Virus Key Company Manufacturing Base & Headquarters Table 12. Global Oncolytic Virus Company, Product Type & Application Table 13. Global Oncolytic Virus Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oncolytic Virus by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Imlygic Table 18. Significant Companies of Oncorine Table 19. Significant Companies of Others Table 20. Global Oncolytic Virus Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Oncolytic Virus Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Oncolytic Virus Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Oncolytic Virus Sales Volume Share by Type (2021-2026) Table 24. Global Oncolytic Virus Sales Volume Share by Type (2027-2032) Table 25. Global Oncolytic Virus Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Oncolytic Virus Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Oncolytic Virus Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Oncolytic Virus Sales Value Share by Type (2021-2026) Table 29. Global Oncolytic Virus Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Melanoma Table 31. Significant Companies of Other Cancers Table 32. Global Oncolytic Virus Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Oncolytic Virus Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Oncolytic Virus Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Oncolytic Virus Sales Volume Share by Application (2021-2026) Table 36. Global Oncolytic Virus Sales Volume Share by Application (2027-2032) Table 37. Global Oncolytic Virus Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Oncolytic Virus Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Oncolytic Virus Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Oncolytic Virus Sales Value Share by Application (2021-2026) Table 41. Global Oncolytic Virus Sales Value Share by Application (2027-2032) Table 42. Global Oncolytic Virus Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Oncolytic Virus Sales by Region (2021-2026) & (K Units) Table 44. Global Oncolytic Virus Sales Market Share by Region (2021-2026) Table 45. Global Oncolytic Virus Sales by Region (2027-2032) & (K Units) Table 46. Global Oncolytic Virus Sales Market Share by Region (2027-2032) Table 47. Global Oncolytic Virus Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Oncolytic Virus Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Oncolytic Virus Sales Value Share by Region (2021-2026) Table 50. Global Oncolytic Virus Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Oncolytic Virus Sales Value Share by Region (2027-2032) Table 52. Global Oncolytic Virus Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Oncolytic Virus Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Oncolytic Virus Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Oncolytic Virus Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Oncolytic Virus Sales by Country (2021-2026) & (K Units) Table 57. Global Oncolytic Virus Sales Market Share by Country (2021-2026) Table 58. Global Oncolytic Virus Sales by Country (2027-2032) & (K Units) Table 59. Global Oncolytic Virus Sales Market Share by Country (2027-2032) Table 60. Global Oncolytic Virus Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Oncolytic Virus Sales Value Market Share by Country (2021-2026) Table 62. Global Oncolytic Virus Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Oncolytic Virus Sales Value Market Share by Country (2027-2032) Table 64. Amgen Company Information Table 65. Amgen Business Overview Table 66. Amgen Oncolytic Virus Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Amgen Oncolytic Virus Product Portfolio Table 68. Amgen Recent Development Table 69. Shanghai Sunway Biotech Company Information Table 70. Shanghai Sunway Biotech Business Overview Table 71. Shanghai Sunway Biotech Oncolytic Virus Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Shanghai Sunway Biotech Oncolytic Virus Product Portfolio Table 73. Shanghai Sunway Biotech Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. Oncolytic Virus Distributors List Table 77. Oncolytic Virus Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Oncolytic Virus Product Image Figure 2. Global Oncolytic Virus Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncolytic Virus Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oncolytic Virus Sales (2021-2032) & (K Units) Figure 5. Global Oncolytic Virus Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Oncolytic Virus Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Imlygic Image Figure 10. Oncorine Image Figure 11. Others Image Figure 12. Global Oncolytic Virus Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Oncolytic Virus Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Oncolytic Virus Sales Volume Share by Type (2021-2032) Figure 15. Global Oncolytic Virus Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Oncolytic Virus Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Oncolytic Virus Sales Value Share by Type (2021-2032) Figure 18. Melanoma Image Figure 19. Other Cancers Image Figure 20. Global Oncolytic Virus Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Oncolytic Virus Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Oncolytic Virus Sales Volume Share by Application (2021-2032) Figure 23. Global Oncolytic Virus Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Oncolytic Virus Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Oncolytic Virus Sales Value Share by Application (2021-2032) Figure 26. Global Oncolytic Virus Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Oncolytic Virus Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Oncolytic Virus Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Oncolytic Virus Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Oncolytic Virus Sales Value (2021-2032) & (US$ Million) Figure 31. North America Oncolytic Virus Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Oncolytic Virus Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Oncolytic Virus Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Oncolytic Virus Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Oncolytic Virus Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Oncolytic Virus Sales Value (2021-2032) & (US$ Million) Figure 37. South America Oncolytic Virus Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Oncolytic Virus Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Oncolytic Virus Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Oncolytic Virus Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Oncolytic Virus Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Oncolytic Virus Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Oncolytic Virus Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Oncolytic Virus Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Imlygic
  • Oncorine
  • Others
Applications
  • Melanoma
  • Other Cancers
Companies covered
  • Amgen
  • Shanghai Sunway Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oncolytic Virus Sales Value (2021-2032)
  4. 1.2.2 Global Oncolytic Virus Sales Volume (2021-2032)
  5. 1.2.3 Global Oncolytic Virus Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oncolytic Virus Market Dynamics
  1. 2.1 Oncolytic Virus Industry Trends
  2. 2.2 Oncolytic Virus Industry Drivers
  3. 2.3 Oncolytic Virus Industry Opportunities and Challenges
  4. 2.4 Oncolytic Virus Industry Restraints
3 Oncolytic Virus Market by Company
  1. 3.1 Global Oncolytic Virus Company Revenue Ranking in 2025
  2. 3.2 Global Oncolytic Virus Revenue by Company (2021-2026)
  3. 3.3 Global Oncolytic Virus Sales Volume by Company (2021-2026)
  4. 3.4 Global Oncolytic Virus Average Price by Company (2021-2026)
  5. 3.5 Global Oncolytic Virus Company Ranking (2024-2026)
  6. 3.6 Global Oncolytic Virus Company Manufacturing Base and Headquarters
  7. 3.7 Global Oncolytic Virus Company Product Type and Application
  8. 3.8 Global Oncolytic Virus Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oncolytic Virus Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oncolytic Virus Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oncolytic Virus Market by Type
  1. 4.1 Oncolytic Virus Type Introduction
  2. 4.1.1 Imlygic
  3. 4.1.2 Oncorine
  4. 4.1.3 Others
  5. 4.2 Global Oncolytic Virus Sales Volume by Type
  6. 4.2.1 Global Oncolytic Virus Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Oncolytic Virus Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Oncolytic Virus Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Oncolytic Virus Sales Value by Type
  10. 4.3.1 Global Oncolytic Virus Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Oncolytic Virus Sales Value by Type (2021-2032)
  12. 4.3.3 Global Oncolytic Virus Sales Value Share by Type (2021-2032)
5 Oncolytic Virus Market by Application
  1. 5.1 Oncolytic Virus Application Introduction
  2. 5.1.1 Melanoma
  3. 5.1.2 Other Cancers
  4. 5.2 Global Oncolytic Virus Sales Volume by Application
  5. 5.2.1 Global Oncolytic Virus Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Oncolytic Virus Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Oncolytic Virus Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Oncolytic Virus Sales Value by Application
  9. 5.3.1 Global Oncolytic Virus Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Oncolytic Virus Sales Value by Application (2021-2032)
  11. 5.3.3 Global Oncolytic Virus Sales Value Share by Application (2021-2032)
6 Oncolytic Virus Regional Sales and Value Analysis
  1. 6.1 Global Oncolytic Virus Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncolytic Virus Sales by Region (2021-2032)
  3. 6.2.1 Global Oncolytic Virus Sales by Region: 2021-2026
  4. 6.2.2 Global Oncolytic Virus Sales by Region (2027-2032)
  5. 6.3 Global Oncolytic Virus Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oncolytic Virus Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oncolytic Virus Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oncolytic Virus Sales Value by Region (2027-2032)
  9. 6.5 Global Oncolytic Virus Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oncolytic Virus Sales Value (2021-2032)
  12. 6.6.2 North America Oncolytic Virus Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oncolytic Virus Sales Value (2021-2032)
  15. 6.7.2 Europe Oncolytic Virus Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oncolytic Virus Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oncolytic Virus Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oncolytic Virus Sales Value (2021-2032)
  21. 6.9.2 South America Oncolytic Virus Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oncolytic Virus Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oncolytic Virus Sales Value Share by Country, 2025 VS 2032
7 Oncolytic Virus Country-level Sales and Value Analysis
  1. 7.1 Global Oncolytic Virus Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncolytic Virus Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oncolytic Virus Sales by Country (2021-2032)
  4. 7.3.1 Global Oncolytic Virus Sales by Country (2021-2026)
  5. 7.3.2 Global Oncolytic Virus Sales by Country (2027-2032)
  6. 7.4 Global Oncolytic Virus Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oncolytic Virus Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oncolytic Virus Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oncolytic Virus Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oncolytic Virus Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oncolytic Virus Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oncolytic Virus Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oncolytic Virus Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oncolytic Virus Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oncolytic Virus Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oncolytic Virus Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oncolytic Virus Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oncolytic Virus Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oncolytic Virus Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oncolytic Virus Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oncolytic Virus Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oncolytic Virus Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oncolytic Virus Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oncolytic Virus Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oncolytic Virus Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oncolytic Virus Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oncolytic Virus Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oncolytic Virus Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oncolytic Virus Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oncolytic Virus Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oncolytic Virus Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oncolytic Virus Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oncolytic Virus Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oncolytic Virus Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oncolytic Virus Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oncolytic Virus Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oncolytic Virus Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oncolytic Virus Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Oncolytic Virus Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Oncolytic Virus Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Shanghai Sunway Biotech
  8. 8.2.1 Shanghai Sunway Biotech Company Information
  9. 8.2.2 Shanghai Sunway Biotech Business Overview
  10. 8.2.3 Shanghai Sunway Biotech Oncolytic Virus Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Sunway Biotech Oncolytic Virus Product Portfolio
  12. 8.2.5 Shanghai Sunway Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oncolytic Virus Value Chain Analysis
  2. 9.1.1 Oncolytic Virus Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oncolytic Virus Sales Mode & Process
  6. 9.2 Oncolytic Virus Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oncolytic Virus Distributors
  9. 9.2.3 Oncolytic Virus Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst